Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in Ethiopia
Immunogenicity of the CpG 1018-Adjuvanted CORBEVAX COVID-19 Vaccine in Adults With and Without Helminth Infection (Schistosoma Mansoni or Hookworm) in Ethiopia
Helminth infections affect over 1.5 billion people and weaken the response to vaccination. CORBEVAX contains the TLR9-activating adjuvant CpG 1018, which may overcome this. This trial measures the immunogenicity of CORBEVAX in adults with and without Schistosoma mansoni or hookworm infection in Ethiopia. The primary measure is spike-specific serum IgG at Day 42; antibody subclass, T-cell, neutralisation and regulatory T-cell responses are measured as secondary outcomes up to Day 90. This is the first of two planned cohorts under a shared protocol; a second cohort receiving an mRNA COVID-19 vaccine at the same sites is planned subject to vaccine availability and will be registered separately.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Adults aged 18 years or older living in helminth -endemic (Schistosoma mansoni and hookworm ) areas of Ethiopia (Bahir Dar and Arba Minch) are recruited by community-based mobilisation, screened by parasitological examination (direct wet mount and Kato-Katz) and classified as helminth-infected or uninfected before enrolment. The study has a single arm: every participant receives CORBEVAX intramuscularly (0.5 ml undiluted) at Day 0 with a homologous booster at Day 28, and the helminth-infected and uninfected groups differ by baseline exposure rather than by assigned intervention. Serum is collected at Day 0, Day 42 and Day 90, and peripheral blood mononuclear cells (PBMC) are isolated at Day 0 and Day 42, so that all cell-based outcomes have a pre-vaccination baseline. Infected participants receive anthelminthic treatment after the Day 42 blood draw. Immunological assays are run at Aarhus University, with neutralizing antibody testing at Biological E, India.
This study is the first of two sequential cohorts conducted under a shared protocol, at the same study sites, with the same field teams, eligibility criteria, visit schedule, outcome measures and laboratory assays. A second cohort, in which participants will receive an mRNA COVID-19 vaccine (BNT162b2, or mRNA-1273 if BNT162b2 cannot be obtained), is planned to begin enrolment approximately one month after the last participant is enrolled in the present cohort, subject to vaccine availability, and will be registered as a separate record carrying the same protocol identifier.
Participants are not allocated to a vaccine platform: the vaccine a participant receives is determined by which cohort is enrolling at the time. Because each cohort contains its own contemporaneous helminth-uninfected comparison group, a prespecified secondary analysis will compare the infected-versus-uninfected response ratio between the two cohorts (a difference-in-differences comparison across vaccine platforms) rather than comparing vaccine groups directly. Serum and PBMC samples from both cohorts will be stored and assayed together in a single batch with shared reference standards and bridging controls, and baseline anti-nucleocapsid serology will be measured in both cohorts to document comparability of prior SARS-CoV-2 exposure. Antigen, dose and formulation differ between the two vaccine platforms, so any between-cohort difference cannot be attributed to adjuvants alone.
A single primary outcome is specified: spike-specific serum IgG concentration at Day 42. Serum is obtained from every participant at every visit and the assay is performed in-house, so this measure is the one least exposed to sample or logistical failure. All remaining immunological read-outs are secondary. Analyses that require viable PBMC will be performed in every participant from whom cells of adequate viability are recovered; if adequate cells are not recovered in a sufficient proportion of participants, those analyses will be reported as exploratory rather than omitted. Serum, PBMC and faecal aliquots are biobanked under the storage consent, so any assay deferred for sample or budget reasons can be completed later rather than lost.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Peter Nejsum, PhD
- Numero di telefono: 4550541392
- Email: pn@clin.au.dk
Backup dei contatti dello studio
- Nome: Bradley Whitehead, PhD
- Email: bradley@clin.au.dk
Luoghi di studio
-
-
Amhara
-
Bahir Dar, Amhara, Etiopia
- Reclutamento
- Andasa Health Centre
-
Contatto:
- Alehegn Abie, MSc
- Numero di telefono: 251932910850
- Email: alehegnab@gmail.com
-
Contatto:
- Desalegn Abebaw
- Numero di telefono: 251912844120
- Email: desalegnabebaw20@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18 or older, in good general health (asymptomatic)
- Willing to participate and give written informed consent
- Infected group: S. mansoni or hookworm eggs on Kato-Katz (two thick smears), S. mansoni at <400 eggs per gram (hookworm cut-off no heavy infection <4,000 eggs)
- Uninfected group: no helminth eggs/protozoan infection on stool examination
Exclusion Criteria:
- Unable to give informed consent
- Pregnancy
- Protozoan infection
- Prior COVID-19 vaccination
- Comorbidity: malaria , active tuberculosis or HIV
- Clinical helminth infection or signs of helminth disease
- Infection intensity above 400 and 4,000 eggs per gram for S. mansoni and hookworm, respectively
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: CORBEVAX in participants with and without helminth
All participants receive CORBEVAX intramuscularly on Day 0 and a booster dose on Day 28 (±3 days). The arm comprises 75 adults with S. mansoni or hookworm infection confirmed by Kato-Katz and 75 adults with no helminth eggs on stool examination; helminth status is a baseline exposure, not an assigned intervention. Infected participants receive anthelminthic treatment after the Day 42 blood sampling. |
Recombinant SARS-CoV-2 receptor-binding-domain protein subunit vaccine adjuvanted with CpG 1018 and alum (Biological E Limited). Two intramuscular doses(0.5 ml/dose), Day 0 and Day 28 (±3 days). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Geometric mean concentration of serum anti-SARS-CoV-2 spike IgG, by helminth infection status
Lasso di tempo: Day 42
|
Concentration of IgG binding the SARS-CoV-2 spike protein in serum, measured by in-house enzyme-linked immunosorbent assay (ELISA) and expressed in arbitrary units per mL (AU/mL). Reported as the geometric mean concentration with 95% confidence interval, separately for participants with and without helminth infection (Kato-Katz positive vs negative at Day 0). Day 42 is 14 days after the second vaccine dose. |
Day 42
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Geometric mean concentration of serum anti-spike IgG at Day 0 and Day 90, by helminth infection status
Lasso di tempo: Day 0 and Day 90
|
Concentration of serum IgG binding the SARS-CoV-2 spike protein, measured by in-house ELISA (AU/mL). Reported as the geometric mean concentration with 95% confidence interval at each time point, by helminth infection status. |
Day 0 and Day 90
|
|
RBD-specific binding antibody concentration (serum IgG)
Lasso di tempo: Day 0, Day 42 and Day 90
|
Concentration of serum IgG binding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, measured by in-house ELISA (AU/mL). Reported as the geometric mean concentration with 95% confidence interval at each time point, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Nucleocapsid-specific binding antibody concentration (serum IgG)
Lasso di tempo: Day 0, Day 42 and Day 90
|
Concentration of serum IgG binding the SARS-CoV-2 nucleocapsid protein, measured by in-house ELISA and expressed in arbitrary units per mL (AU/mL). Anti-nucleocapsid IgG documents prior SARS-CoV-2 exposure, because nucleocapsid is not part of the vaccine, and supports comparability with the planned mRNA cohort. Reported as the geometric mean concentration with 95% confidence interval at each time point, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Concentration of spike-specific IgG subclasses (IgG1, IgG2, IgG3 and IgG4) in serum
Lasso di tempo: Day 0, Day 42 and Day 90
|
Concentration of spike-specific IgG1, IgG2, IgG3 and IgG4 in serum, each measured by in-house subclass-specific ELISA and expressed in arbitrary units per mL (AU/mL). Each subclass is reported separately as the geometric mean concentration with 95% confidence interval at each time point, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Ratio of spike-specific IgG4 to spike-specific IgG1 concentration in serum
Lasso di tempo: Day 0, Day 42 and Day 90
|
Ratio of spike-specific IgG4 to spike-specific IgG1 concentration for each participant, both measured by in-house subclass-specific ELISA (AU/mL) and expressed as a unitless ratio. Reported as the geometric mean ratio with 95% confidence interval at each time point, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Serum SARS-CoV-2 50% neutralising antibody titre (NT50)
Lasso di tempo: Day 0, Day 42 and Day 90
|
Capacity of serum to neutralise SARS-CoV-2, measured by pseudovirus neutralisation assay on serial serum dilutions. Reported as NT50, the reciprocal serum dilution giving 50% reduction in infection (titre units), as the geometric mean titre with 95% confidence interval, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Percentage of CD4+ T cells expressing the transcription factors T-BET, GATA3 and RORγt
Lasso di tempo: Day 0 and Day 42
|
Percentage of CD4+ T cells in PBMC expressing each of three lineage-defining transcription factors: T-BET (Th1), GATA3 (Th2) and RORγt (Th17). Each factor is measured by intranuclear staining and flow cytometry, expressed as % of CD4+ T cells, and reported separately, to assess helminth-related skewing of T cell phenotype. |
Day 0 and Day 42
|
|
Percentage of regulatory T cells among CD4+ T cells
Lasso di tempo: Day 0 and Day 42
|
Percentage of CD4+CD25+FoxP3+ regulatory T cells among total CD4+ T cells in PBMC, measured by flow cytometry with surface and intranuclear staining (% of CD4+ T cells). Reported as the median with interquartile range, by helminth infection status. |
Day 0 and Day 42
|
|
Percentage of CD4+ and CD8+ T cells producing or expressing IFN-γ, TNF-α, IL-2, granzyme B, IL-10 or CD154 after SARS-CoV-2 spike peptide stimulation
Lasso di tempo: Day 0 and Day 42
|
Percentage of CD4+ T cells and, separately, CD8+ T cells in PBMC that produce IFN-γ, TNF-α, IL-2, granzyme B or IL-10, or express the activation marker CD154, after stimulation with SARS-CoV-2 spike peptide pools. Each marker is measured by intracellular cytokine staining and flow cytometry and reported separately as % of the parent T-cell population after subtracting the unstimulated control. |
Day 0 and Day 42
|
|
Serum cytokine and chemokine concentrations
Lasso di tempo: Day 0, Day 42 and Day 90
|
Concentration of Th1-associated (IFN-γ, TNF-α, IL-2, CXCL10) and Th2-associated (IL-4, IL-5, IL-13, CCL17) cytokines and chemokines in serum, each measured by multiplex bead-based immunoassay and expressed in pg/mL. Each analyte is reported separately as the median with interquartile range at each time point, by helminth infection status. |
Day 0, Day 42 and Day 90
|
|
Helminth infection intensity (eggs per gram of stool), by species
Lasso di tempo: Day 0 and Day 90
|
Number of helminth eggs per gram of stool (EPG), measured by Kato-Katz thick smear microscopy. EPG is the mean egg count from two thick smears prepared from a single stool sample, multiplied by 24 (41.7 mg template). Reported separately for Schistosoma mansoni and hookworm as the geometric mean EPG with 95% confidence interval. |
Day 0 and Day 90
|
|
Percentage of participants with parasitological clearance
Lasso di tempo: Day 90
|
Percentage of participants with EPG = 0 on Kato-Katz microscopy at Day 90 among participants with EPG > 0 at baseline, assessed separately for Schistosoma mansoni and hookworm, following anthelmintic treatment given after Day 42. Newly acquired infection (EPG > 0 at Day 90 among participants with EPG = 0 at baseline) will be addressed in a prespecified sensitivity analysis. |
Day 90
|
|
Correlation between baseline helminth egg count and Day 42 anti-spike IgG concentration
Lasso di tempo: Day 0 (EPG) and Day 42 (IgG)
|
Spearman's rank correlation coefficient (rho) between two measures in the same participants: (1) baseline EPG, measured by Kato-Katz thick smear at Day 0 (eggs per gram of stool); and (2) serum anti-spike IgG concentration at Day 42, measured by in-house ELISA (AU/mL). Calculated separately for Schistosoma mansoni and hookworm. Reported with 95% confidence interval. |
Day 0 (EPG) and Day 42 (IgG)
|
|
Correlation between baseline gut microbiota alpha diversity and Day 42 serum anti-spike IgG concentration
Lasso di tempo: Day 0 (microbiota) and Day 42 (IgG)
|
Spearman's rank correlation coefficient (rho) between two measures in the same participants: (1) baseline faecal bacterial alpha diversity, expressed as the Shannon index (unitless), calculated from 16S rRNA gene amplicon sequencing (V3-V4 region) of a single stool sample collected at Day 0; and (2) serum anti-spike IgG concentration at Day 42, measured by in-house ELISA and expressed in arbitrary units per mL (AU/mL). Reported with 95% confidence interval. |
Day 0 (microbiota) and Day 42 (IgG)
|
|
Number and percentage of participants with solicited and unsolicited adverse events after vaccination
Lasso di tempo: Day 0 to Day 90
|
Number and percentage of participants reporting at least one solicited local or systemic adverse event (injection-site pain, redness or swelling, fatigue, headache, fever, myalgia) or any unsolicited adverse event, including serious adverse events, after each vaccine dose. |
Day 0 to Day 90
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie trasmesse da vettori
- Infezioni delle vie respiratorie
- Infezioni
- Infezioni da virus a RNA
- Malattie virali
- Malattie delle vie respiratorie
- Malattie polmonari
- Malattie parassitarie
- Polmonite, virale
- Polmonite
- Infezioni da coronavirus
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- Infezioni secernentee
- Infezioni da nematodi
- Elmintiasi
- Infezioni da trematodi
- Infezioni da Strongilidi
- Schistosomiasi
- COVID-19
- Infezioni da anchilostomi
- Schistosomiasi mansoni
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- AU-ETH-VAC-2026-A
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .